business
AbbVie's biggest deal since 2019 could land soon
Key takeaways
- The price values Apogee at a roughly 60% premium to its closing share price on Thursday, June 18, a steep markup for a company that has never sold a single approved drug.
- Abb Vie usually reaches for biotechs with marketed products or late stage data in hand, not one still years from its first launch.
- An announcement could come as early as Monday, June 22, Reuters noted, provided negotiations wrap up without last-minute issues.
Abb Vie's biggest deal since 2019 could land soon Opeyemi Babalola Sun, June 21, 2026 at 10:07 PM GMT+7 3 min read ABBV Abb Vie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times.
The price values Apogee at a roughly 60% premium to its closing share price on Thursday, June 18, a steep markup for a company that has never sold a single approved drug.
Abb Vie usually reaches for biotechs with marketed products or late stage data in hand, not one still years from its first launch.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop